MBRX - モレキュリン・バイオテック (Moleculin Biotech Inc.) モレキュリン・バイオテック

 MBRXのチャート


 MBRXの企業情報

symbol MBRx
会社名 Moleculin Biotech Inc (モレキュリン・バイオテック)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 Moleculin Biotech Inc. is a preclinical-stage pharmaceutical company. The Company is focused on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin which it refers to as Annamycin an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). Annamycin is a Phase II clinical-stage anthracycline and liposome formulated anthracycline that has been designed to eliminate cardiotoxicity and avoid the multidrug resistance mechanisms. It has over two other drug development projects in progress one involving a portfolio of small molecules which it refers to as the WP1066 Portfolio focused on the modulation of key oncogenic transcription factors involved in the progression of cancer and the WP1122 Portfolio a suite of molecules targeting the metabolic processes involved in cancer in general and glioblastoma. As of April 3 2017 it had not generated any revenue from its operations.   モレキュリン・バイオテックは米国のバイオ医薬品企業。臨床前と臨床段階において、がん治療薬の開発に焦点を当て、テキサス大学システムのMDアンダ―ソン・がんセンタ―とのライセンス契約に基づく。同社候補薬は「リボソ―ム型Annamycin」で、抵抗性急性脊髄性白血病の治療を目指す。本社はテキサス州ヒュ―ストン。   Moleculin Biotech, Inc. is a clinical stage pharmaceutical company, which focuses on the development of oncology drug candidates. Its Annamycin product candidate helps in the treatment of relapsed or refractory acute myeloid leukemia. The company's preclinical small molecule portfolios focus on the modulation of hard-to-target tumor cell signaling mechanisms and the metabolism of tumors. Moleculin Biotech was founded by Walter V. Klemp, Donald H. Picker and Waldemar Priebe on July 28, 2015 and is headquartered in Houston, TX.
本社所在地 5300 Memorial Drive Suite 950 Houston TX 77007 USA
代表者氏名
代表者役職名
電話番号 +1 713-300-5160
設立年月日 42186
市場名 NASDAQ Small Cap
ipoyear 2016年
従業員数
url www.moleculin.com
nasdaq_url https://www.nasdaq.com/symbol/mbrx
adr_tso
EBITDA EBITDA(百万ドル) -13.86700
終値(lastsale) 1.41
時価総額(marketcap) 37874710.77
時価総額 時価総額(百万ドル) 32.50241
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 20.78041
当期純利益 当期純利益(百万ドル) -13.10300
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Moleculin Biotech Inc revenues was not reported. Net loss increased 88% to $7.1M. Higher net loss reflects Research and development increase from $1.2M to $5.5M (expense) Gain from expiration of warrants decrease of 55% to $1M (income) General and administrative increase of 58% to $2.6M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.21 to -$0.28.

 MBRXのテクニカル分析


 MBRXのニュース

   Nasdaq Halts Moleculin Biotech Inc.  2020/05/18 12:47:33 GlobeNewswire
NEW YORK, May 18, 2020 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market® (Nasdaq: NDAQ) announced that the trading halt status in Moleculin Biotech Inc….
   Moleculin Biotech shares remain halted on Nasdaq  2020/05/18 11:39:02 MarketWatch
Moleculin Biotech Inc. undefined said Monday its shares remain halted on Nasdaq with the exchange seeking additional information from the company. Shares…
   Moleculin to Speak on COVID-19 Panel at Maxim Group's Infectious Disease Virtual Conference  2020/04/29 11:30:00 PR Newswire
HOUSTON, April 29, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that Walter Klemp, Chairman and Chief…
   Moleculin Approved to Accelerate European Clinical Trial  2020/04/28 11:30:00 PR Newswire
HOUSTON, April 28, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates, today announced that it is now authorized by the Polish Department of Registration of…
   Moleculin Biotech, Inc. (MBRX) Flat As Market Gains: What You Should Know  2020/04/27 21:45:21 Zacks Investment Research
Moleculin Biotech, Inc. (MBRX) closed the most recent trading day at $1.14, making no change from the previous trading session.
   Moleculin to Speak on COVID-19 Panel at Maxim Group's Infectious Disease Virtual Conference  2020/04/29 11:30:00 PR Newswire
HOUSTON, April 29, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that Walter Klemp, Chairman and Chief…
   Moleculin Approved to Accelerate European Clinical Trial  2020/04/28 11:30:00 PR Newswire
HOUSTON, April 28, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates, today announced that it is now authorized by the Polish Department of Registration of…
   Moleculin Biotech, Inc. (MBRX) Flat As Market Gains: What You Should Know  2020/04/27 21:45:21 Zacks Investment Research
Moleculin Biotech, Inc. (MBRX) closed the most recent trading day at $1.14, making no change from the previous trading session.
   Is Moleculin Biotech (MBRX) Stock Outpacing Its Medical Peers This Year?  2020/04/27 15:30:12 Zacks Investment Research
Is (MBRX) Outperforming Other Medical Stocks This Year?
   Moleculin Announces Agreement with ImQuest Biosciences to Expand Coronavirus Testing  2020/04/20 11:30:00 PR Newswire
HOUSTON, April 20, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates, today announced that it has entered into an agreement with ImQuest Biosciences to expand in…
   Is Moleculin Biotech (MBRX) Outperforming Other Medical Stocks This Year?  2020/04/09 15:30:11 Zacks Investment Research
Is (MBRX) Outperforming Other Medical Stocks This Year?
   Why Moleculin Biotech’s Coronavirus Treatment Could Be Huge  2020/04/08 14:26:52 24/7 Wall street
   Thinking about buying stock in Camber Energy, Cypress Semiconductor, Delta Air Lines, Moleculin Biotech, or TOP Ships?  2020/04/08 13:31:00 PR Newswire
NEW YORK, April 8, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CEI, CY, DAL, MBRX, and TOPS. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   Moleculin Biotech Doubles In Pre-Market Trading On Potential Covid-19 Treatment  2020/04/08 12:48:13 Smarter Analyst
Moleculin Biotech (MBRX) today announced that independent research found 2-deoxy-D-glucose (“2-DG”) to reduce the virus that causes COVID-19 by 100% in in vitro … The post Moleculin Biotech Doubles In Pre-Market Trading On Potential Covid-19 Treatment appeared first on Smarter Analyst .
   Moleculin Signs Agreement with UTMB to Test WP1122 on a Range of Viruses, Including Coronavirus  2020/03/17 11:30:00 Benzinga Feeds
HOUSTON , March 17, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (NASDAQ: MBRX ) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, announced that it has entered into an agreement with the University of Texas Medical Branch at Galveston (UTMB) to conduct research on Moleculin's patented portfolio of molecular inhibitors, including drug candidate, WP1122, for antiviral properties against a range of viruses, including Coronavirus. UTMB's Center for Biodefense and Emerging Infectious Diseases collaborates with the Galveston National Laboratory, which is funded by NIAID, the U.S. Department of Defense, the U.S. Centers for Disease Control & Prevention and other federal agencies, as well as academic partners, private foundations, and the biopharmaceutical industry. "Published research has revealed that viral replication can be highly dependent on specific monosaccharides and has demonstrated the effectiveness of a compound known as '2-DG,' a dual decoy of glucose and mannose, in the treatment of certain viruses 1 ," commented Walter Klemp , Moleculin's Chairman and CEO. "And, this is rooted in an emerging field of research focused on the role of glycolysis and glycosylation, or more specifically, on glucose and mannose metabolism in viral activity, including the coronavirus 2 .

 関連キーワード  (医薬品 米国株 モレキュリン・バイオテック MBRX Moleculin Biotech Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)